Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Physics

Immunology

Medicine

Microbiology

Internal Medicine

Show all topics

DOI

10.1016/s0140-6736(21)02717-3

License

CC-BY

Other Formats

PDF